Navigation Links
Catalyst Biosciences Receives Milestone Payment from Pfizer for Progress in Lead Hemostasis Program
Date:12/16/2010

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2010 /PRNewswire/ -- Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced the receipt of a $4.0 million milestone payment from Pfizer Inc. under the terms of the collaboration agreement for the development of improved recombinant human Factor VIIa variants for the treatment of hemophilia and other bleeding disorders.  

"We are very encouraged by the progress made to date in our Factor VIIa program, the most advanced program within Catalyst's hemostasis franchise," said Nassim Usman, Ph.D., Catalyst's CEO.  "In addition to our work with Pfizer, Catalyst has independently achieved significant progress in engineering highly differentiated recombinant human Factor IX and Xa variants for acute and prophylactic treatment of bleeding disorders, including both hemophilia and non-hemophilia indications.  Catalyst expects to expand and strengthen this pipeline of novel engineered proteases in the coming year." 

In June 2009 Catalyst and Wyeth LLC (the successor to Wyeth), a wholly owned subsidiary of Pfizer Inc., formed an exclusive, worldwide collaboration for the discovery, development and commercialization of improved, second generation Factor VIIa products.  Total payments under the collaboration, including an upfront payment of $21 million, ongoing research funding, and milestone payments, could exceed $500 million, exclusive of double-digit royalty payments.  

About Catalyst Biosciences  Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases that target proteins underlying diseases.  Catalyst's discovery platform rapidly creates and optimizes tailor-made protease drug candidates that cleave a wide variety of disease targets, either by improving existing protease drugs or by creating new protease drugs, known as Alterase™ therapeutics.  Catalyst is focusing its product development efforts on drug candidates for hemophilia, non-hemophilic bleeding, and complement-driven diseases, including the prevention of delayed graft function and inflammation.  Catalyst has ongoing research, development, and license agreements with Wyeth Pharmaceuticals, a wholly owned subsidiary of Pfizer Inc. and MedImmune, LLC, the global biologics unit of AstraZeneca plc.  Catalyst is privately held with backing by leading venture firms, including Burrill & Company, Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures, and Sofinnova Ventures.  For more information, please visit www.catbio.com.Catalyst Biosciences, Inc.

William J. Dawson

Chief Financial Officer

+1.650.871.0761

info@catbio.com

BCC Partners for Catalyst Biosciences

Karen L. Bergman or Michelle Corral

+1.650.575.1509 or +1.415.794.8662
'/>"/>

SOURCE Catalyst Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Catalyst Pharmaceutical Partners to Present at the MoneyShow Conference
2. Catalyst Pharmaceutical Partners Regains Compliance with NASDAQ Minimum Bid Price Rule
3. Catalyst Pharmaceutical Partners to Present at the BioNetwork East 2010 Conference
4. Catalyst Pharmaceutical Partners to Present Today at 2010 Epilepsy Pipeline Update Conference
5. Catalyst Pharmaceutical Partners Selected to Present at Epilepsy Conference Highlighting New and Promising Therapies
6. IDEXX Laboratories Announces Catalyst Dx(R) Placement Total for 2009 and Installed Base of SmartService(TM) Customers
7. Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results
8. Catalyst Pharmaceutical Partners, Inc. Announces Organizational Changes and Extension of Chief Executives Employment Agreement
9. Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering
10. Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market
11. Catalyst Pharmaceutical Partners, Inc. To Raise $3.97 Million In Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2017)... 11, 2017  Thornhill Research Inc. ( ... an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by ... Commercial Corporation (CCC) ( Ottawa, Ontario, Canada ... administer general anesthesia to patients requiring emergency medical ... US Marine Corps have been a longtime partner ...
(Date:5/10/2017)... 10, 2017 Global Health Intelligence (GHI), ... America , published its 2017 ranking of the ... on extensive data analysis from GHI,s hospitals database for ... for the region. The GHI database covers 86% of the ... than 130 data points for each institution in key areas ...
(Date:5/10/2017)... May 10, 2017 Radiology has become the ... costs have also spiraled to the number one ranking ... radiology than ever before as the most complete and ... patient with lower back pain an MRI may confirm ... for pain, resulting in entirely different treatment protocols.  In ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 26, 2017 , ... Boar’s Head Brand®, one of the ... Day entertaining that are sure to satisfy your guests’ flavor cravings, while adding ... cheeses featured in these refreshingly balanced recipes are packed with flavor, creating the ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... is focusing on the Peace Agreements being discussed by President Donald Trump and the ... race to try to speed up peace talks in the continuous battle between Israel ...
(Date:5/26/2017)... ... May 26, 2017 , ... “When the Stars Lead Home”: ... the creation of published author Laura Weigel Douglas, an avid reader who lives in ... house that sometimes feels like Green Hills Adventure Camp. She couldn’t be more grateful. ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... “Cactus Jack: ... had on so many others. “Cactus Jack: Against All Odds” is the creation ... Walter D. Hubbard is married to Jack Carlisle’s third child Jane. Walter. ...
(Date:5/24/2017)... ... 2017 , ... Dr. Alan I. Benvenisty, MD is dual board certified in ... known for his distinguished expertise and experience in the diagnosis and treatment of vascular ... treating renovascular disease and aortic aneurysm . He is known for his minimally ...
Breaking Medicine News(10 mins):